Status:
COMPLETED
A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study
Lead Sponsor:
Peplin
Conditions:
Actinic Keratosis
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed to follow up patients, who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57 in the PEP005-020 study, over a 12 month period to assess both recurrence...
Eligibility Criteria
Inclusion
- Inclusion
- Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures
- Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected treatment area at the Day 57 visit in study PEP005-020
- Exclusion
- Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)
- Early termination from study PEP005-020
Exclusion
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00952783
Start Date
July 1 2009
End Date
October 1 2010
Last Update
March 26 2015
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Park Avenue Dermatology
Orange Park, Florida, United States, 32073
2
Medaphase Inc
Newnan, Georgia, United States, 30263
3
Gwinnett Clinical Research Centre
Snellville, Georgia, United States, 30078-3250
4
Michigan Center for Research Corp
Clinton Twp, Michigan, United States, 48038